Reading and Resources
Resources for Providers and Patients
- American Cancer Society. Breast Cancer Facts & Figures. https://www.cancer.org/research/cancer-facts-statistics/breast-cancer-facts-figures.html
- American Society of Clinical Oncology. Breast cancer guidelines. http://asco.org/research-guidelines/quality-guidelines/guidelines/breast-cancer
- Association of Cancer Care Centers. https://www.accc-cancer.org/home/learn/cancer-types/breast-cancer/supportive-care-strategies-for-promoting-health-equity-in-patients-with-breast-cancer
- Breastcancer.org. Breast Cancer Facts and Statistics. http://www.breastcancer.org/symptoms/understand_bc
- Centers for Disease Control and Prevention (CDC). Breast cancer. http://cancer.org/cancer/breast-cancer.html
- European Society for Medical Oncology. Oncology Pro: Oncology in practice. https://oncologypro.esmo.org/Oncology-in-Practice
- National Comprehensive Cancer Network (NCCN). Breast Cancer. https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1419
- Survivorship care plan. http://www.oncolink.org/frequently-asked-questions/coping-with-cancer-nutrition-survivorship/making-a-survivorship-care-plan
Articles and Further Reading
- Brufsky A, Maculaitis MC, Kopenhafer L, et al. Identifying drivers of first-line HR+/HER2- metastatic breast cancer treatment choices. Future Oncol. 2024;20(29):2165-2177.
- Cardoso F, Bese N, Distelhorst SR, et al. Supportive care during treatment for breast cancer: resource allocations in low- and middle-income countries. A Breast Health Global Initiative 2013 consensus statement. Breast. 2013;22(5):593-605.
- Das A, Lavanya KJ, Nandini, et al. Effectiveness of selective estrogen receptor modulators in breast cancer therapy: an update. Curr Med Chem. 2023;30:3287-3314.
- Feng Y, Spezia M, Huang S, et al. Breast cancer development and progression: risk factors, cancer stem cells, signaling pathways, genomics, and molecular pathogenesis. Genes Dis. 2018;5(2):77-106.
- Jerzak KJ, Bouganim N, Brezden-Masley C, et al. HR+/HER2- advanced breast cancer treatment in the first-line setting: expert review. Curr Oncol. 2023;30(6):5425-5447.
- Kida K, Olver I, Yennu S, et al. Optimal supportive care for patients with metastatic breast cancer according to their disease progression phase. JCO Oncol Pract. 2021;17(4):177-183.
- Loibl S, Furlanetto J. Integrating CDK4/6 inhibitors in the treatment of patients with early breast cancer. Breast. 2022;62:S70-S79.
- Ray SK, Mukherjee S. Breast cancer stem cells as novel biomarkers. Clin Chim Acta. 2024;557:117855.
- Rugo HS. Addressing unmet need in the management of patients with ER+/HER2-, ESR1-mutated metastatic breast cancer: clinician’s perspective. Clin Adv Hematol Oncol. 2023;21:623-632.
- Smolarz B, Nowak AZ, Romanowicz H. Breast cancer: epidemiology, classification, pathogenesis and treatment (review of literature). Cancers (Basel). 2022;14(10):2569.
- Tan PH, Ellis I, Allison K, et al, WHO Classification of Tumours Editorial Board. The 2019 World Health Organization classification of tumours of the breast. Histopathology. 2020;77(2):181-185.
- Wang X, Zhao S, Xin Q, et al. Recent progress of CDK4/6 inhibitors’ current practice in breast cancer. Cancer Gene Ther. 2024;31:1283-1291.
- Wysocka J. New WHO classification of breast tumours. J Oncol. 2020;70:250-252. https://onlinelibrary.wiley.com/doi/full/10.1111/his.14091
